A practical reference on albumin conjugate: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-21 and is reviewed periodically as new material appears.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
=== Bacterial susceptibility === Cefuroxime axetil treats infections against methicillin-, oxacillin- and penicillin-sensitive bacterial strains. Cefuroxime axetil does not work against enterococci. Gram-positive aerobic microorganisms
1 January – New Year's Day 2 January – Day after New Year's Day 6 February – Waitangi Day 18 April – Good Friday 21 April – Easter Monday 25 April – Anzac Day 2 June – King's Birthday 20 June – Matariki 27 October – Labour Day 25 December – Christmas Day 26 December – Boxing Day
Endogenous Originating from within an organism, tissue, or cell. In neuroscience, it typically refers to naturally occurring neurotransmitters or signaling molecules. Endorphins Endogenous opioid peptides that bind to opioid receptors and act as natural painkillers and mood enhancers. Engram A theoretical physical trace or biological substrate of memory in the brain. The term is used in memory research to describe the neural changes underlying a specific memory. Enteric nervous system A subdivision of the autonomic nervous system that governs the function of the gastrointestinal system. Sometimes called the "second brain." Epinephrine A hormone and neurotransmitter (also known as adrenaline) involved in the body’s fight-or-flight response. Produced in the adrenal medulla. EPSP (Excitatory Postsynaptic Potential) A depolarizing event in a postsynaptic neuron caused by the influx of positive ions, making the neuron more likely to fire an action potential. Equilibrium potential The membrane potential at which there is no net flow of a particular ion across the cell membrane. It can be calculated using the Nernst equation. Estrogen A steroid hormone that, in addition to reproductive functions, affects brain structure, cognition, and neuroprotection, particularly in areas such as the hippocampus. Evoked potential A measured electrical response of the nervous system to a specific sensory, motor, or cognitive stimulus, commonly recorded with EEG. Excitability The ability of a neuron or muscle cell to respond to a stimulus and generate an action potential.
Bavaria (The geographically distinct Palatinate, which was part of Bavaria, 1816–1946, is now part of Rheinland Pfalz). Bremen Hamburg Hesse Saxony Thuringia The other 11 states of the Weimar Republic either merged into one another or were separated into smaller entities:
Sources: en.wikipedia.org
== External links == Clinical trial number NCT03349060 for "Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-1)" at ClinicalTrials.gov Clinical trial number NCT03575871 for "Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-2)" at ClinicalTrials.gov Clinical trial number NCT03720470 for "Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (JADE Compare)" at ClinicalTrials.gov
The presence of breast implants currently presents no contraindication to breast feeding, and there is no evidence to support that the practice may present health issues to a breastfeeding infant. Women with breast implants may have functional breast-feeding difficulties; mammoplasty procedures that feature periareolar incisions are especially likely to cause breastfeeding difficulties. Surgery may also damage the lactiferous ducts and the nerves in the nipple-areola area. Functional breastfeeding difficulties arise if the surgeon cut the milk ducts or the major nerves innervating the breast, or if the milk glands were otherwise damaged. Milk duct and nerve damage are more common if the incisions cut tissue near the nipple. The milk glands are most likely to be affected by subglandular implants and by large-sized breast implants, which pinch the lactiferous ducts and impede milk flow. Small-sized breast implants and submuscular implantation cause fewer breast-function problems; however, it is impossible to predict whether a woman who undergoes breast augmentation will be able to successfully breast feed since some women are able to breast-feed after periareolar incisions and subglandular placement and some are not able to after augmentation using submuscular and other types of surgical incisions.
Fibroblast activation protein alpha (FAP-alpha) also known as prolyl endopeptidase FAP is an enzyme that in humans is encoded by the FAP gene. Prolyl endopeptidase FAP is a 170 kDa membrane-bound gelatinase. It was independently identified as a surface glycoprotein recognized by the F19 monoclonal antibody in activated fibroblasts and a Surface Expressed Protease (seprase) in invasive melanoma cells.
Sources: en.wikipedia.org
The pulmonary trunk divides into pulmonary arteries and progressively smaller arteries throughout the lungs, until it reaches capillaries. As these pass by alveoli carbon dioxide is exchanged for oxygen. This happens through the passive process of diffusion. In the left heart, oxygenated blood is returned to the left atrium via the pulmonary veins. It is then pumped into the left ventricle through the mitral valve and into the aorta through the aortic valve for systemic circulation. The aorta is a large artery that branches into many smaller arteries, arterioles, and ultimately capillaries. In the capillaries, oxygen and nutrients from blood are supplied to body cells for metabolism, and exchanged for carbon dioxide and waste products. Capillary blood, now deoxygenated, travels into venules and veins that ultimately collect in the superior and inferior vena cavae, and into the right heart.
== pKa calculation methods == Several software packages and webserver are available for the calculation of protein pKa values. Note that the pKHHa value does in general depend on the pH value. This dependence is small for weakly interacting groups like well solvated amino acid side chains on the protein surface, but can be large for strongly interacting groups like those buried in enzyme active sites or integral membrane proteins. While many protein pKa prediction methods are available, their accuracies often differ significantly due to subtle and often drastic differences in strategy.
{\displaystyle {\frac {\mathrm {d} \left[\mathrm {M} _{1}\right]}{\mathrm {d} \left[\mathrm {M} _{2}\right]}}={\frac {\left[\mathrm {M} _{1}\right]\left(r_{1}\left[\mathrm {M} _{1}\right]+\left[\mathrm {M} _{2}\right]\right)}{\left[\mathrm {M} _{2}\right]\left(\left[\mathrm {M} _{1}\right]+r_{2}\left[\mathrm {M} _{2}\right]\right)}}}
In 1985, Kidder expressed ambivalence toward continuing her career, and was quoted as saying: "I don't feel comfortable as a performer and I'm a big turkey as a movie star." She stated that the quote was reported out of context, but conceded: "I am in a weird frame of mind at the moment. I know acting is not going to be enough for me for the rest of my life. This business is very hard on women at a certain age, and I never want to end up just having to accept what's offered me. So, I am anxious to direct, to have options." In 1986, she was selected as the English narrator for the Japanese animated series The Wonderful Wizard of Oz. In 1987, Kidder reprised her Lois Lane role in Superman IV: The Quest for Peace (1987), which she filmed in 1986. Body of Evidence (1988), a CBS Movie of the Week, cast Kidder as a nurse who suspects that her medical pathologist husband is a serial killer.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.